Cargando…
Organoid technology for personalized pancreatic cancer therapy
BACKGROUND: Pancreatic ductal adenocarcinoma has the lowest survival rate among all major cancers and is the third leading cause of cancer-related mortality. The stagnant survival statistics and dismal response rates to current therapeutics highlight the need for more efficient preclinical models. P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985124/ https://www.ncbi.nlm.nih.gov/pubmed/33492660 http://dx.doi.org/10.1007/s13402-021-00585-1 |